Allena Pharmaceuticals, Inc. EBIT

EBIT of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBIT growth rates and interactive chart. Earnings before interest and taxes is an indicator of a company's profitability. One can calculate it as revenue minus all expenses, excluding tax and interest. EBIT is also referred to as operating earnings, operating profit, and profit before interest and taxes. It is the amount of profit that a company earns before interest on debt and taxes are paid.


Highlights and Quick Summary

  • EBIT for the quarter ending March 31, 2022 was $-11.6 Million (a 14.19% increase compared to previous quarter)
  • Year-over-year quarterly EBIT decreased by -15.56%
  • Annual EBIT for 2021 was $-95.3 Million (a 48.97% increase from previous year)
  • Annual EBIT for 2020 was $-64 Million (a -31.83% decrease from previous year)
  • Annual EBIT for 2019 was $-93.8 Million (a 31.82% increase from previous year)
  • Twelve month EBIT ending March 31, 2022 was $-47.8 Million (a 0.31% increase compared to previous quarter)
  • Twelve month trailing EBIT increased by 11.15% year-over-year
Trailing EBIT for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
$-47.8 Million $-47.6 Million $-47.5 Million $-43 Million
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBIT of Allena Pharmaceuticals, Inc.

Most recent EBITof ALNA including historical data for past 10 years.

Interactive Chart of EBIT of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. EBIT for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $-11.56
2021 $-10.12 $-12.43 $-13.69 $-11.41 $-95.3
2020 $-9.99 $-7.92 $-6.56 $-7.52 $-63.97
2019 $-11.29 $-13.34 $-11.34 $-11.56 $-93.84
2018 $-9.78 $-9.71 $-8.14 $-7.97 $-71.19
2017 $-6.57 $-4.36 $-4.48 $-5.54 $-41.9
2016 $-6.1 $-24.19
2015 $-13.91

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.